Disease · MONDO_0001708
Targets92
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 92
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 11 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| CHRNA4 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist | Phase 1/2 | https://conductscience.org/library/genes/1137 | Drugs and targets |
| CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist | Phase 1/2 | https://conductscience.org/library/genes/1141 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| CSF1 | Macrophage colony-stimulating factor 1 | 1 | Macrophage colony-stimulating factor 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1435 | Drugs and targets |
| CSF2 | Granulocyte-macrophage colony-stimulating factor | 1 | Granulocyte-macrophage colony-stimulating factor inhibitor | Phase 2 | https://conductscience.org/library/genes/1437 | Drugs and targets |
| EDNRA | Endothelin receptor, ET-A/ET-B | 1 | Endothelin receptor, ET-A/ET-B antagonist | Phase 2 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| EDNRB | Endothelin receptor, ET-A/ET-B | 1 | Endothelin receptor, ET-A/ET-B antagonist | Phase 2 | https://conductscience.org/library/genes/1910 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 1 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| MT-ND1 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4535 | Drugs and targets |
| MT-ND2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4536 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001708/targets